期刊文献+

肾上腺嗜铬细胞瘤术后原位复发伴骶椎转移1例

In situ recurrence and sacral metastasis after surgery:a case of adrenal pheochromocytoma
原文传递
导出
摘要 报道1例肾上腺嗜铬细胞瘤术后原位复发伴骶椎转移。患者为36岁男性,16年前行左肾上腺嗜铬细胞瘤手术,术后血压正常。2年前出现血压升高。正电子发射断层显像-CT提示左肾上腺后上方及骶椎处存在病变,诊断为左肾上腺嗜铬细胞瘤原位复发伴脊柱转移,经多学科会诊后行手术治疗。左肾上腺嗜铬细胞瘤原位复发伴脊柱转移相关报道少,缺乏标准治疗方案,本文通过对该病例进行研究探讨,以期为该病的临床诊疗提供帮助。
作者 吴霞 徐瑞 于晓倩 黄文 郑飞 赵学强 李欣然 段艳华 Wu Xia;Xu Rui;Yu Xiaoqian;Huang Wen;Zheng Fei;Zhao Xueqiang;Li Xinran;Duan Yanhua(Department of Cardiology,Shandong Provincial Qianfoshan Hospital,Shandong University,Jinan 250014,China;Department of Cardiology,the First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Jinan 250014,China;Department of Medical Ultrasound,the First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Jinan 250014,China;Department of Nuclear Medicine,the First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Jinan 250014,China)
出处 《中华内科杂志》 CAS CSCD 北大核心 2022年第11期1260-1262,共3页 Chinese Journal of Internal Medicine
基金 山东省自然科学基金(ZR2019PH057)。
  • 相关文献

参考文献2

二级参考文献22

  • 1祝宇,王卫庆,沈永倩,吴瑜璇,张翀宇,芮文斌,周文龙,孙福康,刘定益,邵远,沈周俊,毕宇芳,苏颋为,姜蕾,宁光.嗜铬细胞瘤术前的高血压控制与术中高容量血液稀释[J].临床泌尿外科杂志,2006,21(8):571-573. 被引量:3
  • 2Gonias S, high-dose Goldsby R, Matthay KK, et al. Phase α study of [6131I]metaiodobenzylguanidine therapy for patients metastatic pheochromocytoma and paragangfioma[J]. J Clin Oncol, 2009, 27(25):4162-4168.
  • 3Huang H, Abraham J, Hung E , et al. Treatment of malignant pheo- with cydophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients[J]. Cancer, 2008, 113(8):2020-2028.
  • 4Salmenkivi K, Heikkila P, LiuJ, et al. VEGF in 105 pheochromocy- tomas: enhanced expression correlates with malignant outcome[J]. APMIS, 2003, 111 (4) :458-464.
  • 5Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas[J].J Clin Endocrinol Metab, 2012, 97 (11) :4040-4050.
  • 6Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role ofso- matostatin analogues in the treatment of neuroendocrine tumours [J]. Mol Cell Endocrinol, 2008, 286(1-2):238-250.
  • 7Kulke MH, Stuart K, Enzinger PC, et al. Phase α study of temo- zolomide and thalidomide in patients with metastatic neuroendo- crine tumors[J].J Clin Oncol, 2006, 24(3):401-406.
  • 8Druce MR, Kaltsas GA, Fraenkel M, et al. Novel and evolving ther- apies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)[J]. Horm Metab Res, 2009, 41 (9):697-702.
  • 9Parenti G, Zampetfi B, Rapizzi E, et al. Updated and new perspec- tives on diagnosis, prognosis, and therapy of malignant pheochro- mocytomMparaganglioma[J].J Oncol, 2012, 2012:872713.
  • 10Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of sys- temic chemotherapy for patients with metastatic pheochromocyto- mas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience[J]. Cancer, 2012, 118(11): 2804-2812.

共引文献131

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部